The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Dupixent peak sales ambition raised to more than €13 billion
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Lifts full-year outlook as obesity drug boom accelerates
Subscribe To Our Newsletter & Stay Updated
